IMODIUM MULTI-SYMPTOM RELIEF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IMODIUM MULTI-SYMPTOM RELIEF (IMODIUM MULTI-SYMPTOM RELIEF).
Loperamide binds to mu-opioid receptors in the intestinal wall, reducing peristalsis and increasing intestinal transit time, thereby allowing for greater absorption of water and electrolytes. Simethicone reduces surface tension of gas bubbles, facilitating their coalescence and expulsion.
| Metabolism | Loperamide is extensively metabolized by CYP2C8 and CYP3A4, with minor contributions from CYP2D6. Simethicone is not absorbed and is excreted unchanged in feces. |
| Excretion | Fecal: ~60% (loperamide and metabolites); Renal: ~1-2% (unchanged loperamide and glucuronide conjugates); Biliary: minimal, as loperamide undergoes extensive enterohepatic recirculation. |
| Half-life | Terminal elimination half-life is approximately 9-14 hours (mean 11 hours) in plasma; in clinical context, it supports twice-daily dosing for chronic diarrhea. |
| Protein binding | ~97% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 2.5-3.0 L/kg; high Vd indicates extensive tissue distribution beyond the central compartment, consistent with peripheral opiate receptor binding. |
| Bioavailability | Oral: ~0.3-0.5% (low due to extensive first-pass metabolism); rectally: ~50% (bypasses first-pass effect to some extent). |
| Onset of Action | Oral: ~4-6 hours for full antidiarrheal effect; however, initial slowing of gastrointestinal motility begins within 1-3 hours after a single dose. |
| Duration of Action | Up to 12-24 hours after a single oral dose; clinical notes: duration may be prolonged in patients with hepatic impairment (due to reduced first-pass metabolism) or in cases of overdose. |
| Molecular Weight | 513.5 |
4 mg orally initially, then 2 mg after each unformed stool; maximum 8 mg/day for OTC use (prescription up to 16 mg/day). Route: oral.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: use with caution; consider dose reduction due to reduced first-pass metabolism and increased systemic exposure. |
| Pediatric use | Children 6–11 years: 2 mg initially, then 1 mg after each unformed stool; maximum 6 mg/day. Children 12–17 years: same as adult dosing. Weight-based: not required; age-based dosing is standard. |
| Geriatric use | No specific dose adjustment; monitor for constipation and central nervous system effects due to potential increased sensitivity. |
| 1st trimester | Loperamide is generally avoided in first trimester due to lack of data and potential risk of congenital malformations, though studies are inconsistent. Animal studies have shown no teratogenicity at clinically relevant doses. |
| 2nd trimester | Caution advised; use only if clearly needed. Human data limited but no consistent evidence of fetal harm. Simethicone (combination component) is not absorbed and considered safe. |
| 3rd trimester | Caution advised near term; loperamide may stimulate uterine contractions via opioid-like effects on smooth muscle at high doses, though clinically significant effects are rare at therapeutic doses. |
Clinical note
Comprehensive clinical and safety monograph for IMODIUM MULTI-SYMPTOM RELIEF (IMODIUM MULTI-SYMPTOM RELIEF).
| Placental transfer | Limited data; loperamide likely crosses placenta to some extent due to molecular weight <500 Da and lipophilicity, but transfer is expected to be low based on animal studies. Simethicone does not cross placenta due to high molecular weight and lack of absorption. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to loperamide or simethiconeAcute diarrhea with high fever or bloody stools (possible bacterial enterocolitis)Known or suspected intestinal obstructionToxic megacolonAcute ulcerative colitisChildren under 6 years of age (for this specific product)Known galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (due to excipients)
| Precautions | Avoid use in patients with bloody diarrhea, high fever, or suspected bacterial enterocolitis. Do not use if diarrhea is accompanied by mucus or if abdominal pain is severe. Discontinue if no improvement within 48 hours. Risk of QT prolongation and torsades de pointes at high doses. Use with caution in hepatic impairment. |
| Food/Dietary | Avoid alcohol, caffeine, and dairy products as they can exacerbate diarrhea or cause additional GI upset. High-fiber foods may interfere with loperamide absorption; separate by at least 2 hours. Grapefruit juice may increase loperamide levels via CYP3A4 inhibition; limit intake. No specific food restrictions beyond general diarrhea management. |
Loading safety data…
| Breastfeeding |
| Loperamide is excreted into breast milk in small quantities (less than 2% of maternal weight-adjusted dose), unlikely to affect nursing infant. Simethicone is not absorbed and not excreted. However, consider alternative treatments if possible due to limited safety data in neonates. |
| Lactation Rating | L2 (Possibly Compatible; limited data suggest low risk) |
| Teratogenic Risk | Limited human data; animal studies show no teratogenic risk at therapeutic doses. Use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor for maternal constipation, abdominal pain, and signs of ileus. Fetal assessment per standard obstetric care. |
| Fertility Effects | No known adverse effects on fertility in animal studies; human data lacking. |
| Clinical Pearls | IMODIUM MULTI-SYMPTOM RELIEF contains loperamide 2 mg and simethicone 125 mg per tablet. Loperamide is a peripheral mu-opioid receptor agonist that slows GI motility and enhances water and electrolyte absorption. Simethicone is a surfactant that reduces gas bloating. Onset of action is 1-3 hours; duration ~6 hours. Can prolong QT interval at high doses. Contraindicated in bloody diarrhea, febrile illness, or suspected bacterial enterocolitis. Not recommended in children <6 years. Do not exceed 8 mg/day (OTC) unless directed by physician. Can cause constipation if overused. |
| Patient Advice | Take 2 tablets after first loose stool, then 1 tablet after each subsequent loose stool; do not exceed 4 tablets in 24 hours unless directed by a doctor. · Do not use if you have bloody or black stools, mucus in stool, fever, or if you have had diarrhea for more than 2 days. · Stop use and consult a doctor if diarrhea persists beyond 48 hours or if symptoms worsen. · Chew or swallow tablets whole with water; do not crush or break. · Drink plenty of clear fluids to prevent dehydration; avoid alcohol, caffeine, and dairy products as they may worsen diarrhea. · Do not take with other medications containing loperamide or similar antidiarrheals. · Store at room temperature, away from moisture and heat. · If you have a history of heart disease (QT prolongation), consult a doctor before use. |